Michael A. Schmid

Michael A. Schmid has a diverse work experience in the field of biomedical research and immunology. Michael A. started their career as a Student Researcher at the Children's Cancer Institute Australia, where they focused on oncology and leukemia drug resistance. Michael A. then pursued their education and worked as a Student Researcher at the University of Stuttgart, where they studied the molecular regulation of cell migration.

After completing their studies, Schmid worked as a PhD Student at the Institute for Research in Biomedicine, specializing in inflammation-driven regeneration of dendritic cell subsets. Michael A. then joined the University of Zurich as a Postdoctoral Researcher, focusing on dendritic cell function in regulating inflammation.

Schmid expanded their expertise further at the University of California Berkeley, where they worked as a Postdoctoral Researcher investigating immunity to dengue and influenza virus infections. Michael A. uncovered the role of mosquito saliva in dengue pathogenesis during their tenure.

In 2016, Schmid joined KU Leuven as a Senior Scientist, optimizing the delivery of yellow fever-based vaccines. Their research involved intradermal vaccination against various flaviviruses and the development of live-attenuated virus vaccine candidates.

Currently, Schmid is associated with Vir Biotechnology, Inc. Since 2018, they have held multiple roles, including Principal Scientist, Associate Director, and Director, leading various research teams. Their work primarily focuses on monoclonal antibody Fc engineering, pre-clinical development, and bioanalytics. Michael A. has been instrumental in the development and optimization of mAb candidates against virus targets, including SARS-CoV-2, HIV, influenza virus, and hepatitis B and D virus.

Throughout their career, Schmid has demonstrated strong leadership skills, line management experience, and a proficiency in scientific writing. Michael A. has authored scientific manuscripts and reports for IND submissions.

Michael A. Schmid received their Doctor of Natural Sciences (Dr. rer. nat) degree in Immunology from the University of Tübingen in 2010. Prior to that, they completed a Diploma (equivalent to BSc & MSc) in Technical Biology at the University of Stuttgart from 1999 to 2005. Additionally, they participated in a study abroad program at UNSW in 2002-2003, where they studied Virology, Immunology, and Biopharmaceuticals.